Bespak Achieves Sustainability Milestone With First Life Cycle Assessment for Pressurized Metered Dose Inhaler Valve

Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), recently announced it has completed its first life cycle assessment (LCA) for its market-leading BK357 pressurized Metered Dose Inhaler (pMDI) valve. This important step comes as a result of Bespak’s commitment to looking beyond low Global Warming Potential (GWP) propellants for opportunities to reduce carbon footprint in the pharma industry.

The completion of Bespak’s first LCA marks a significant milestone that has been achieved as part of Bespak’s overarching sustainability strategy. It follows Bespak’s investment in manufacturing capabilities at clinical and commercial scale for low carbon pMDIs incorporating the low GWP propellants, HFA-152a & HFO-1234ze.

The project was undertaken to better understand the carbon impact of Bespak’s materials and manufacturing processes, and to increase transparency in the supply chain for pMDIs. The LCA has been independently verified by expert sustainability scientists from Tunley Environmental in line with ISO 14067:2018 standards. A verified LCA certification for industry partners using the BK357 valve will enable them to leverage robust, science-led insights that can support transparency in their sustainability reporting, sustainable procurement frameworks and the transition to net zero carbon emissions. The LCA also provides clear direction for future carbon reduction initiatives at Bespak, including emission-saving opportunities in the material and energy stages of the product life cycle.

Chris Hirst, CEO of Bespak, said: “The completion of the LCA for our widely used and trusted BK357 pMDI valve demonstrates Bespak’s active commitment to championing sustainability in the supply chain for the benefit of customers, patients and the planet. We are excited to be actively researching solutions for carbon reduction beyond the propellant switch, and are proud to provide credible, independently verified data to back up our environmental claims.”

Benedicta Bakpa, Head of ESG at Bespak, commented: “This important milestone signifies our ongoing commitment to transparency and accountability in driving sustainable operations. As part of our overarching sustainability initiatives, we continue to identify opportunities to reduce our carbon footprint and work towards our near- and long-term net zero targets.”

Bespak is a specialist global contract development and manufacturing organization (CDMO) solely focused on the inhaled and nasal drug delivery industry. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical market. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.

With a long history in the development and commercial supply of pressurized Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators. Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. The company has both established capacity and ongoing expansions to enable the manufacture of pMDIs with low Global Warming Potential (GWP) propellants, making it well positioned to lead the green pMDI transition. More information: www.bespak.com.